{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:05:09Z","timestamp":1777183509709,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-024-05956-3","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:03:00Z","timestamp":1727157780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sintilimab plus GemOx is an effective salvage therapy in patients with refractory\/relapsing nodal peripheral T cell lymphomas"],"prefix":"10.1007","volume":"150","author":[{"given":"Xibin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"6","key":"5956_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","volume":"19","author":"SK Barta","year":"2019","unstructured":"Barta SK, Zain J, MacFarlane AT et al (2019) Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma[J]. Clin Lymphoma Myeloma Leuk 19(6):356\u2013364. https:\/\/doi.org\/10.1016\/j.clml.2019.03.022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"5956_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood-2019-126194","volume":"134","author":"NN Bennani","year":"2019","unstructured":"Bennani NN, Pederson LD, Atherton P et al (2019) A Phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma[J]. Blood 134(1):467","journal-title":"Blood"},{"issue":"27","key":"5956_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"10","key":"5956_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M et al (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry[J]. Blood 124(10):1570\u20131577. https:\/\/doi.org\/10.1182\/blood-2014-04-573089","journal-title":"Blood"},{"issue":"6","key":"5956_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","volume":"20","author":"D Fiore","year":"2020","unstructured":"Fiore D, Cappelli LV, Broccoli A et al (2020) Peripheral T cell lymphomas: from the bench to the clinic[J]. Nat Rev Cancer 20(6):323\u2013342. https:\/\/doi.org\/10.1038\/s41568-020-0247-0","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"5956_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","volume":"107","author":"AM Garcia-Sancho","year":"2022","unstructured":"Garcia-Sancho AM, Bellei M, Lopez-Parra M et al (2022) Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study[J]. Haematologica 107(11):2675\u20132684. https:\/\/doi.org\/10.3324\/haematol.2021.279426","journal-title":"Haematologica"},{"key":"5956_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang J, Shu Y et al (2022) Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ 377:e68714. https:\/\/doi.org\/10.1136\/bmj-2021-068714","journal-title":"BMJ"},{"issue":"10","key":"5956_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","volume":"128","author":"H Miyoshi","year":"2016","unstructured":"Miyoshi H, Kiyasu J, Kato T et al (2016) PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma[J]. Blood 128(10):1374\u20131381. https:\/\/doi.org\/10.1182\/blood-2016-02-698936","journal-title":"Blood"},{"issue":"1","key":"5956_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/16078454.2019.1590965","volume":"24","author":"H Shen","year":"2019","unstructured":"Shen H, Ji Y, Zhou D et al (2019) Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis[J]. Hematology 24(1):392\u2013398. https:\/\/doi.org\/10.1080\/16078454.2019.1590965","journal-title":"Hematology"},{"issue":"8","key":"5956_CR10","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. Ann Oncol 26(8):1766\u20131771. https:\/\/doi.org\/10.1093\/annonc\/mdv237","journal-title":"Ann Oncol"},{"issue":"1","key":"5956_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z et al (2021) Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)[J]. J Hematol Oncol 14(1):12. https:\/\/doi.org\/10.1186\/s13045-021-01033-1","journal-title":"J Hematol Oncol"},{"issue":"9","key":"5956_CR12","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3390\/cancers14092332","volume":"14","author":"D Sibon","year":"2022","unstructured":"Sibon D (2022) Peripheral T-cell lymphomas: therapeutic approaches[J]. Cancers 14(9):2332","journal-title":"Cancers"},{"issue":"25","key":"5956_CR13","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van Besien K et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma[J]. J Clin Oncol 31(25):3100\u20133109. https:\/\/doi.org\/10.1200\/JCO.2012.46.0188","journal-title":"J Clin Oncol"},{"issue":"3","key":"5956_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z et al (2012) Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification[J]. Am J Clin Pathol 138(3):429\u2013434. https:\/\/doi.org\/10.1309\/AJCP7YLTQPUSDQ5C","journal-title":"Am J Clin Pathol"},{"issue":"20","key":"5956_CR15","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"1","key":"5956_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao R, Fan L, Song Y et al (2021) Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)[J]. Signal Transduct Target Ther 6(1):365. https:\/\/doi.org\/10.1038\/s41392-021-00768-0","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"5956_CR17","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol 26(25):4124\u20134130. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558","journal-title":"J Clin Oncol"},{"issue":"12","key":"5956_CR18","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun J, Wang Z et al (2021) Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study[J]. J Thorac Oncol 16(12):2109\u20132120. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.015","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05956-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T03:35:34Z","timestamp":1728444934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05956-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["5956"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05956-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Our study complies with the Declaration of Helsinki and was approved by the hospital ethics committee. (IR2022495).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was waived due to the retrospective, non-interventional nature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}],"article-number":"425"}}